Hepion Pharmaceuticals, Inc. (HEPA)
NASDAQ: HEPA · IEX Real-Time Price · USD
1.410
+0.120 (9.30%)
Apr 26, 2024, 12:26 PM EDT - Market open
Hepion Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for HEPA.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for HEPA is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|
| Strong Buy | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 7, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $70 | Buy | Initiates | $70 | +4,864.54% | Feb 28, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-11.66
from -12.32
EPS Next Year
-5.30
from -11.66
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 232.1M |
| Avg | n/a | n/a | n/a | n/a | 225.4M |
| Low | n/a | n/a | n/a | n/a | 216.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -12.00 | -5.46 |
| Avg | -11.66 | -5.30 |
| Low | -11.20 | -5.10 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.